Previous 10 |
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases...
Shares of Alector Inc ( ALEC ) have risen by just 6% from its February 2019 IPO price point of $19. At the time the company took in around $176 million in proceeds (not including underwriter option of 1,387,500 shares). Investment banks involved included Morgan Stanley, BofA Merill Lynch, ...
Alector (NASDAQ: ALEC ): Q1 GAAP EPS of -$0.42 misses by $0.15 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Dosed first frontotemporal dementia patient with AL001 in the Phase 1b portion of the INFRONT clinical study Dosed first Alzheimer’s disease patient with AL002 in the Phase 1b portion of the INVOKE clinical study Initiated Phase 1 first-in-human clinical trial of AL003, calle...
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced that members of the management team will prese...
Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh...
- Phase 1b study of AL002 enrolling Alzheimer’s disease patients will assess safety and pharmacodynamics, and will monitor target specific biomarkers SOUTH SAN FRANCISCO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company...
Alector (NASDAQ: ALEC ) announces that the first patient with frontotemporal dementia (FTD) has been dosed in the Phase 1b portion of its INFRONT study assessing the safety of multiple doses of AL001, a monoclonal antibody designed to modulate a protein expressed by nerve cells call...
Phase 1 healthy volunteer portion of the AL001 study successfully met its primary objective of safety and demonstrated proof-of-mechanism in the central nervous system (CNS) Phase 1b study of AL001 enrolling frontotemporal dementia (FTD) patients with a mutation in the progranulin ge...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...